Iris H. Kloots

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Journal: Prostate cancer and prostatic diseases

Published: January 03, 2026

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.

Journal: British journal of cancer

Published: December 03, 2024

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.

Journal: Theranostics

Published: February 01, 2024

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.

Journal: International journal of molecular sciences

Published: April 19, 2023

Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.

Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.

Journal: European urology oncology

Published: April 13, 2023

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer.

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer.

Journal: Cancers

Published: April 07, 2023

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting.

Journal: European urology open science

Published: November 23, 2022

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.

Journal: British journal of cancer

Published: February 25, 2022

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.

Journal: British journal of cancer

Published: August 24, 2021

Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer.

Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer.

Journal: JCO precision oncology

Published: November 01, 2020

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.

Journal: International journal of cancer

Published: June 22, 2020

Showing 1-11 of 11

Last Updated: 09/26/2026